Sustained Efficacy and Safety of Seladelpar for up to 36 Months in Patients With Primary Biliary Cholangitis From the Placebo-Controlled RESPONSE Study to the Open-Label ASSURE Study

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Sustained Efficacy and Safety of Seladelpar for up to 36 Months in Patients With Primary Biliary Cholangitis From the Placebo-Controlled RESPONSE Study to the Open-Label ASSURE Study

	AASLD 2025 Nov 7-11 Wash DC Cynthia Levy